

### **REMARKS**

Claims 4-7 are currently pending and under examination. Claims 4 and 7 have been amended. Support for these amendments can be found throughout the specification. No new matter has been added. Entry, reexamination and reconsideration in light of the preceding amendments and following remarks are respectfully requested.

#### **Double Patenting**

Claims 4-7 stand rejected under the doctrine of obviousness-type double patenting in view of the claims 1-115 of copending Application Serial No. 10/464,410 (Applicants' Reference No. 068911-0023). Applicants respectfully request that this double patenting rejection be held in abeyance until there is an indication of allowable subject matter in the present application.

Claims 4-7 are provisionally rejected under the doctrine of obviousness-type double patenting in view of the claims 1-34 of copending Application Serial No. 10/464,834 (Applicants' Reference No. 068911-0012). Applicants respectfully request that this double patenting rejection be held in abeyance until there is an indication of allowable subject matter in the present application.

Claims 4-7 are provisionally rejected under the doctrine of obviousness-type double patenting in view of the claims 1-12 of U.S. Application Serial No. 11/689,856, now U.S. Patent No. 7,270,835 (Applicants' Reference No. 068911-0060). Applicants respectfully request that this double patenting rejection be withdrawn as the patented claims differ significantly from claim 4-7 recited in the present application.

Claims 4-7 are provisionally rejected under the doctrine of obviousness-type double patenting in view of the claims 1-6 of U.S. Application Serial No. 10/774,048, now abandoned (Applicants' Reference No. 068911-0062). Applicants respectfully request that this double patenting rejection be withdrawn as Application Serial No. 10/774,048 is now abandoned.

Claims 4-7 are provisionally rejected under the doctrine of obviousness -type double patenting in view of the claims 1-115 of copending U.S. Application Serial Nos. 11/344,555 (Applicants' Reference No. 068911-0141), 11/344,556 (Applicants' Reference No. 068911-0142)

and 11/344,557 (Applicants' Reference No. 068911-0139). Applicants respectfully request that these double patenting rejections be held in abeyance until there is an indication of allowable subject matter in the present application.

Claims 4-7 are provisionally rejected under the doctrine of obviousness -type double patenting in view of the claims 1-34 of copending U.S. Application Serial Nos. 11/344,552 (Applicants' Reference No. 068911-0138), 11/344,554 (Applicants' Reference No. 068911-0136) and 11/403,034 (Applicants' Reference No. 068911-0147). Applicants respectfully request that these double patenting rejections be held in abeyance until there is an indication of allowable subject matter in the present application.

Claims 4-7 are provisionally rejected under the doctrine of obviousness-type double patenting in view of the claims 1-12 of copending Application Serial No. 10/789,817 (Applicants' Reference No. 068911-0074). Applicants respectfully request that this double patenting rejection be held in abeyance until there is an indication of allowable subject matter in the present application.

**Claim Rejections – 35 U.S.C. § 112, First Paragraph**

Claims 4-6 are rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking written description support for “reduced isoalpha acid (RIAA) isolated from hops.” The Examiner suggests amending the claims to read “derived from hops.” Applicants agree with the Examiner and have amended the claims accordingly. Applicant respectfully request that this rejection be withdrawn.

**Claim Rejections – 35 U.S.C. § 112, Second Paragraph**

Claim 7 stand rejected under 35 U.S.C. § 112, second paragraph, as being uncertain in scope due to the abbreviations recited in this claim. Applicants have amended the claim and have spelled out the abbreviations for RIAA and IAA. Accordingly, Applicants respectfully request that this rejection be withdrawn.

**Conclusion**


In light of the amendments and remarks herein, Applicants submit that the claims are now in condition for allowance and respectfully request a notice to this effect. If there are any

outstanding issues that might be resolved by an interview or an Examiner's amendment, the Examiner is requested to call Applicant's agent at the telephone number shown below.

To the extend necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to deposit account 50-1133 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDermott Will & Emery LLP



Atabak R. Royae, Reg. No. 59,037

McDermott Will & Emery, LLP

28 State Street

Boston, MA 02109-1775

Tel: (617) 535-4108

Fax: (617) 535-3800

Date: Aug. 1, 2008